Decisions reaffirm Viatris' ability to provide patient access to interchangeable Semglee®
PITTSBURGH , Dec. 29, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) announced that it is pleased with decisions issued today which affirm the U.S. Patent and Trademark Appeal Board's prior rulings that found the challenged claims of Sanofi's Lantus® SoloSTAR® device patents, U.S. Patent Nos. 9,603,044, 8,992,486, 9,526,844, 9,604,008, and 8,679,069, unpatentable.
These affirmances reinforce the company's continuing efforts to break down barriers to patient access for important medicines such as Semglee® through its Global Healthcare Gateway®. Viatris and Biocon Biologics Ltd. launched their interchangeable Semglee® products (insulin glargine-yfgn) last month, which are the first, and currently the only, interchangeable biosimilars to Lantus®, providing more affordable options for the millions of Americans living with diabetes.
The Semglee® products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, Lantus®, allowing for substitution at the pharmacy counter. Semglee® is indicated to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
About Viatris Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020 , Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 38,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad , India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements about the outcome and status of ongoing litigation. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to: the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings; that court decisions are not yet final and are subject to further review, rehearing and appeal, which could result in an adverse outcome; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; the integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the "Upjohn Business"), which combined to form Viatris (the "Combination") and the implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies and operating efficiencies in connection with the Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture and commercialize products; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations, including our operations in China ; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks Viatris' filings with the Securities and Exchange Commission. Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-wins-court-decisions-on-sanofi-appeals-of-lantus-patent-invalidations-301451703.html
Facebook appears on its way to getting the renewable energy it wants to power new data center operations in Hillsboro. The power will come through the data center owner, QTS Data Centers, which will use a Portland General Electric program that makes it possible for big power users to source newly developed renewable energy while remaining a PGE customer.
Wood believes we're still in a strong bull market. Take advantage.
EV stocks are being dumped as a group today, even with these three names reporting good news recently.
Losing money in the S&P 500 is never fun. But it stings all the more when everyone else is making tons on their stocks.
Yahoo Finance Live's Jared Blikre examines the latest market action, in addition to reporting on Biogen undergoing acquisition negotiations by Samsung
A cosmetics and skin care products company founded by married Taiwanese actors Zhang Ting and Lin Ruiyang has had assets worth 600 million yuan (US$94 million) frozen due to an investigation by China's market regulator over an alleged pyramid scheme. The market regulator in Shijiazhuang, the capital of northern China's Hebei province, said it had received several reports about a suspected pyramid scheme involving Shanghai Dowell Trading, according to a letter widely circulated on Chinese social
Get aboard the Tesla stock train, argues Dan Ives at Wedbush.
Biogen, which owns nearly half of a Samsung unit, shares surged Wednesday. A South Korean newspaper reported that Samsung wants to buy Biogen for as much as $42 billion.
These stocks are trading near their 52-week lows but have tremendous long-term growth opportunities.
The rally in Victoria's Secret may just be getting started, contends JP Morgan retail analyst Matt Boss.
The stock has already managed to settle below the $115 level and is moving towards yearly lows at $108.70.
Nio (NYSE: NIO) has managed to make a place for itself in the domestic Chinese market. Nio has grown significantly in the seven years since its founding in November 2014. Nio's year-to-date deliveries through Nov. 30 rose 120.4% year over year.
(Bloomberg) -- SenseTime Group Inc. co-founder Tang Xiao’ou has become one of the world’s richest people, after the Chinese AI champion blew past concerns about American sanctions to surge as much as 23% on its Hong Kong debut.Most Read from BloombergGhislaine Maxwell Found Guilty in Win for Epstein VictimsMercedes Swept Up in China Internet Furor Over Models’ EyesApple Aims to Prevent Defections to Meta With Rare $180,000 Bonuses for Top TalentThe Senator Who Could Rescue Biden’s AgendaCovid Wi
Despite their similar names, the Vanguard Total Stock Market Index and the Vanguard 500 Index funds have different objectives.
Berkshire Hathaway is the ultimate Warren Buffett stock. But is it a good buy? Here's what the earnings and chart show for Berkshire stock.
Wednesday will go down in history for Codex DNA (NASDAQ: DNAY). The genetics-focused biotech saw its share price rocket 39% higher, thanks to a potentially very lucrative deal with a deep-pocketed pharmaceutical giant. Codex DNA disclosed in a regulatory filing that it has entered into a research collaboration and license agreement with U.S. pharmaceutical company Pfizer (NYSE: PFE), these days best known as the co-developer of the Comirnaty coronavirus vaccine.
If you feel like inflation is outpacing the cost-of-living adjustment (COLA) planned for everyone's Social Security checks beginning in January, you're not being unreasonable. It's a fact of life that too many must-have things rose in price more than the 5.9% COLA increase scheduled for 2022. The good news is, having a stake in the right dividend stocks can help many investors more than offset this likely shortfall.
Dynavax Technologies (NASDAQ: DVAX), a biotech considered by some to be a coronavirus stock, outpaced the broader market on Wednesday. On Tuesday, India's Biological E announced that its coronavirus vaccine candidate Corbevax had received approval for emergency use from that country's pharmaceutical regulator, the Drugs Controller General.
Each of them truly requires a multi-year holding period to overcome their current relatively rich valuations and get the most out of them. You may not have heard the name BlackRock (NYSE: BLK), but you probably are familiar with at least one of its biggest businesses. BlackRock is the company behind the iShares family of exchange-traded funds (ETFs); it also manages traditional mutual funds and serves as the backbone for many institutional retirement plans.
(Bloomberg) -- Mukesh Ambani, Asia’s richest man, wants to expedite Reliance Industries Ltd.’s leadership transition and sees his $217 billion empire scaling new heights under his three children.Most Read from BloombergGhislaine Maxwell Found Guilty in Win for Epstein VictimsApple Aims to Prevent Defections to Meta With Rare $180,000 Bonuses for Top TalentMercedes Swept Up in China Internet Furor Over Model’s EyesThe Senator Who Could Rescue Biden’s AgendaCovid With Omicron Isn’t ‘Same Disease,’